Clinical Trial Update: Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects [Phase 4]

View source ↗

Summary

Phase 4 safety and efficacy study of Flebogamma 5% DIF IGIV in pediatric patients with primary immunodeficiency disease; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Disease

Drugs mentioned

• Flebogamma 5% DIF IGIV (intravenous immunoglobulin)

Snippet

Sponsor: Instituto Grifols, S.A. | Conditions: Primary Immune Deficiency Disease | Phase 4 | Status: COMPLETED | Results posted: 2016-12-08